Business
Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021
- Preclinical Work Supports the Development of LP-184 in Prostate Cancer with DNA Damage Repair Aberrations DALLAS, March 23, 2021 /PRNewswire/ -- Lantern
About this update from Lantern Pharma Inc.
[{"type":"text","content":"- Preclinical Work Supports the Development of LP-184 in Prostate Cancer with DNA Damage Repair Aberrations\n\n\nDALLAS, March 23, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"A.I.\") platform to transform oncology drug discovery and development, will present new data on LP-184, a next-generation, targeted small molecule in the acylfulvene drug class, showcasing its potency across various 2D and 3D models of prostate cancer, at the American Association for Cancer Research (AACR) Virtual Annual Meeting, taking place from April 10-15, 2021.\n\n \n \n \n \n \n \n\n \nLantern's poster will highlight the spectrum of DNA damage repair defects, occurring in 25-30% of metastatic castration resistant prostate cancer (mCRPC) patients, against which LP-184 shows nanomolar potency. \"In vitro studies of LP-184 continue to show potentially best in class efficacy in metastatic prostate cancer with a novel mechanism of action,\" stated Panna Sharma, CEO and President of Lantern Pharma. \"Our ongoing work of LP-184 in metastatic prostate cancer in collaboration with Georgetown University has shown effectiveness in tumor models with mutations in DNA damage repair pathway components including in genes involved in Homologous Recombination and Transcription Coupled-Nucleotide Excision Repair. We look forward to sharing this new data at AACR and developing this compound towards the clinic and for the benefit of prostate cancer patients.\"\nDetails of the abstract are as follows:\nTitle: LP184, a novel alkylating agent, is efficacious in prostate cancer models with DNA damage repair defectsSession Category: Experimental and Molecular TherapeuticsSession Title: Novel Antitumor AgentsPermanent Abstract Number: 1249The full text of the abstract is now available on the AACR Annual Meeting 2021 website.The accompanying poster will be available to view to registered participants during the conference via the AACR e-poster website on April 10, 2021, and published on the company website after the conference.\nContactMarek Ciszewski, JDDirector, Investor [email protected]\nAbout Lantern Pharma\nLantern Pharma (LTRN) is a clinical-stage biopharmaceutical company leveraging advances in genomics, artificial intelligence, and machi...